LongevityEpitalonEpithalon

Epitalon

AEDG tetrapeptide · Khavinson pineal bioregulator

Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) created in Russia as a defined analog of epithalamin, an extract of the pineal gland. It is marketed aggressively as a 'telomerase activator,' a telomere lengthener, and an anti-aging / lifespan-extending peptide. The honest problem is not that there is no research — it is that almost all of the research comes from a single source. The foundational studies were produced by one research lineage (Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — the same institute that commercializes these 'peptide bioregulators'), cluster in 2002–2004, appear mostly in low-impact translated Russian journals, and have almost never been independently replicated. The famous 'telomerase' result is a single ~2003 experiment in human cells in a dish, not in people. One of the few semi-independent tests actually found NO effect on melatonin, contradicting the 'restores your body clock' marketing. The human 'prolongs life' claim comes from a cohort that — though indexed as a randomized trial — reports no blinding or design detail and comes from the commercializing group, and it studied the pineal extract, not necessarily this synthetic peptide. There are zero registered clinical trials, no validated human pharmacokinetics, and a US compounding status still unsettled: the FDA placed Epitalon on its Category 2 503A list in 2023 and removed it from that list in April 2026, pending a July 2026 advisory-committee (PCAC) review — removal is not approval. This page documents what the primary studies actually show and is explicit about the single-source, unreplicated nature of the evidence.

The short version

Epitalon is a tiny synthetic peptide — just four amino acids strung together (Ala-Glu-Asp-Gly). It was designed in Russia as a clean, defined version of 'epithalamin,' which is an extract made from the pineal gland (a small hormone-producing structure in the brain). It is sold online as one of the most popular 'anti-aging' peptides, usually with the headline claim that it switches on telomerase, the enzyme that maintains the protective caps on your chromosomes.

Here is the honest catch. The reason to be cautious about Epitalon is not that no studies exist — it is that nearly all of them come from one place. A single Russian research group (and the institute it works at, which also sells these peptides) produced almost all of the positive findings, mostly twenty-plus years ago, in journals that are rarely read or replicated in the wider scientific world.

The celebrated 'telomerase' finding was a single experiment in human cells growing in a dish — not in living people. And one of the very few studies done partly by an outside group actually found that Epitalon did NOT change melatonin secretion, which directly undercuts the common marketing line that it 'resets your body clock.' The human 'it makes people live longer' claim comes from a study that — although it is listed as a randomized trial — reports no blinding or design detail and was run by the group that sells the peptide, and that tested the pineal extract rather than this exact peptide.

On top of that, there are no registered clinical trials of Epitalon, no reliable measurement of how long it lasts in the body, and an unsettled US compounding status: the FDA placed it on its Category 2 503A list in 2023 and removed it in April 2026, pending a July 2026 advisory-committee review. None of this proves Epitalon does nothing — but it does mean the confident telomere-and-longevity story sold around it is not backed by the kind of independent, repeated evidence that claim would require. This page lays out exactly what the real studies show and where they stop.

Molecular identity

Specs

Molecular weight: 390.35 g/mol
Molecular formula: C14H22N4O9
Monoisotopic mass: 390.13868 Da
Sequence (4 AA): Ala-Glu-Asp-Gly (AEDG), all-L

Structure / class: Synthetic tetrapeptide; defined analog of epithalamin (a bovine pineal-gland peptide extract — not the same as this single molecule)PubChem CID 219042; Khavinson group
CAS / UNII: 307297-39-8 (also 64082-79-7) · O65P17785GPubChem CID 219042
Water solubility: Highly water-soluble (computed XLogP −5.5; reconstituted in bacteriostatic water)PubChem CID 219042 (computed)
Molecular target: No classic receptor identified; claimed telomerase (hTERT) activation / gene-expression modulator — shown only in vitro in human fibroblasts (single source)PMID 12937682
Half-life: Not established (no published human pharmacokinetic study; vendor '~30 min' is not from a primary PK source)Not establishedHalf-life curve →
Regulatory status: Not FDA-approved; removed from FDA 503A Category 2 (Apr 2026), pending PCAC review (Jul 2026) — removal is not approval; epithalamin extract registered in RussiaFDA / Russian Drug Directory

Plain English

Mechanism

Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG). It was developed by the Khavinson group as a chemically defined analog of epithalamin — and it is worth being precise here, because the two are routinely confused: epithalamin is a bovine pineal-gland peptide EXTRACT (an undefined mixture), whereas Epitalon is the single, defined four-residue peptide. Claims demonstrated for one are often transferred to the other in marketing; this page keeps them separate.

The marquee mechanistic claim is telomerase activation. The primary source is a 2003 study reporting that adding Epitalon to cultured human fetal fibroblasts induced expression of the telomerase catalytic subunit (hTERT), increased telomerase activity, and lengthened telomeres, with a companion paper claiming the cells overcame their normal division limit. The crucial qualifier: this was demonstrated IN VITRO — in human cells in culture — by the originating group, and it has not been independently replicated or shown in living humans. A separate paper from the same group proposed that Epitalon directly binds promoter DNA sequences to switch on gene transcription, but that is a speculative molecular hypothesis, not a confirmed cellular mechanism.

The pineal/circadian story is where the evidence actively cuts against the marketing. A semi-independent study (a French chronobiology group with Khavinson as co-author) tested Epitalon on melatonin secretion from perfused rat pineal glands of young and old animals and found NO significant effect at any concentration or age. So the widely promoted idea that Epitalon 'restores melatonin' or 'resets the circadian clock' is not supported by the one experiment that directly looked — and is contradicted by it.

Stepping back: the proposed mechanisms (telomerase induction, gene-transcription effects, antioxidant and pineal-regulatory actions) come almost entirely from a single research lineage, are largely in vitro or in rodents, are decades old, and lack independent replication. An independent 2025 review called the peptide 'promising' and its mechanistic rationale plausible, while flagging the key gaps — an evidence base that is decades old, limited structural data, and the absence of independent replication and regulatory-grade toxicology; on our reading those gaps leave the evidence short of what clinical translation would require. The honest mechanistic summary is: an interesting hypothesis built on unreplicated, single-source data — not an established mechanism in humans.

Sources:PubChem CID 219042 PMID 12937682 PMID 15455129 PMID 14666197 PMID 12809170 PMID 40141333

Why people reach for it

Potential benefits

Epitalon is the most-reached-for of the Khavinson 'bioregulator' peptides — the anti-aging headliner of the family. Here's what draws people to it, kept honest about how thin the evidence underneath actually is.

The flagship 'cellular aging' peptide — Its whole reputation rests on a single ~2003 lab-dish experiment in which Epitalon switched on telomerase (hTERT) and lengthened telomeres in human cells — the result people reach for it on, even though it has never been replicated or shown in a living person.
A pineal / body-clock angle people pursue — Epitalon was built as an analog of a pineal-gland extract, and users take it hoping to support nighttime melatonin and circadian rhythm — worth flagging honestly that the one direct test of this found no effect on melatonin, so it's an aspiration, not a demonstrated action.
The headline longevity bioregulator — Within the Khavinson family it's the one with rodent lifespan data (≈13% mean-lifespan increase in one mouse strain) and an elderly-cohort mortality report — which is why it anchors community longevity protocols, with the caveat that the human data are single-source and unblinded.
Runs as a short, defined course — Unlike daily-indefinite peptides, Epitalon is used in brief pulsed courses (often 10–20 days) repeated a couple of times a year — a defined, contained way to use it that suits the bioregulator pattern.
Pairs within the bioregulator family — Because the Khavinson concept assigns a different peptide to each tissue, Epitalon is commonly stacked with family members like Thymalin or Pinealon — though doing so multiplies the same single-source speculation rather than adding independent support.

Sources:PMID 12937682 PMID 12809170 PMID 12459848 PMID 14523363 PMID 40141333

What people reach for Epitalon for, drawn from what the research reports (overwhelmingly single-source, decades-old, mostly in-vitro or rodent) and how it's used — not proven human outcomes or medical claims.

Implied timing

Best time to dose

Implied best time

Bedtime

Most people take Epitalon in the evening, at or near bedtime, lining it up with the pineal gland's natural nighttime activity.

Epitalon was designed as an analog of a pineal-gland extract, and the pineal does its work at night — releasing melatonin and running the body's circadian timing. A bedtime dose is the community's way of matching the peptide to that nighttime window.
This is the strongest timing rationale in the bioregulator family: where the other Khavinson peptides have no circadian logic at all, Epitalon's whole proposed identity is pineal/circadian, so evening lines up with its claimed mechanism more naturally.
Honesty check on that rationale: the one direct experiment that tested Epitalon on melatonin secretion found no effect, so the evening logic is reasoned from its proposed role, not a proven circadian action. It's a low-cost, sensible habit — not a studied schedule.
Epitalon is run in short pulsed courses (often 10–20 days), so what matters more than the exact hour is holding the same bedtime slot consistently across the course.

No study establishes an ideal time of day for Epitalon — this is reasoned from its proposed pineal/circadian mechanism and how it's used. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for Epitalon the lean is the evening/bedtime end of it.

How to run it

Dosing & protocol

Epitalon is dosed here as a subcutaneous injection — the form sold as a research peptide and the route the on-page calculator is built for. Unlike most peptides in this catalog, there is no convention dose range backed even by a practitioner consensus: Epitalon has no registered human clinical trial and no published human pharmacokinetics. The widely-circulated milligram 'protocols' trace not to a primary human study but to backward extrapolation from the rodent lifespan work and the original Khavinson injection courses. What follows describes the structural pattern those sources used — short pulsed courses, repeated periodically — framed honestly as community convention, not dosing evidence.

No established human dose: Epitalon has zero registered clinical trials and no published human PK. The ~30-minute half-life and specific milligram amounts circulated by vendors are not from any primary human pharmacokinetic study. Every number below is community convention extrapolated from animal and unblinded human-cohort data — not a validated human protocol.

Dose — no established human dose

Convention framed as convention: community protocols exist, but no human trial has validated them.

Convention range:: Community protocols typically cite 5–10 mg per course, split across 10–20 daily injections of 0.5–1 mg each. This range is not derived from any human dose-finding study; it is back-extrapolated from the rodent lifespan work (1 mg SC × 5/week, lifelong in mice) and from the Khavinson injection-course pattern in elderly humans. There is no published human dose-response data.
Route:: Subcutaneous injection — all primary studies that used administered Epitalon used either SC (rodent lifespan work) or injectable courses SC/IM (Khavinson human cohort). This is the only route for which any study data exists; oral bioavailability is not validated for this peptide.
Why not more specific:: No dose-escalation trial, no human PK study, and no independently replicated human study exist. Quoting a precise 'recommended' milligram dose would be fabricating an evidence base that does not exist.

Subcutaneous administration

Epitalon is injected into subcutaneous fat; site, rotation, and timing are the actionable choices.

Injection site:: The abdomen (a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites across the multi-day course so the same spot is not used on consecutive days — this avoids local irritation and fatty-tissue changes (lipohypertrophy).
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. The reconstitution card below converts convention doses to syringe units at the standard mix; the on-page calculator does it for any vial size.
Time of day:: Evening, at or near bedtime, is the community preference — see Best time to dose above. The reasoning is Epitalon's proposed pineal/melatonin mechanism (the pineal gland is active at night); that rationale is speculative given that the one direct melatonin-secretion test showed no effect, but evening timing is low-cost and is the dominant convention.
Food window:: Subcutaneous Epitalon does not compete with food for absorption; it can be injected independently of meals.

Cycle & washout

The structural feature shared by every primary Epitalon and epithalamin study is pulsing — short courses repeated after a gap, not continuous daily use.

Course length:: 10–20 consecutive daily injections is the pattern from the original Khavinson human work (injectable epithalamin courses repeated over years) and from community convention for the synthetic peptide. Courses shorter than ~10 days are common in practice.
Washout:: A gap of several months before repeating — the Khavinson human cohort repeated courses periodically across 6–8 years of follow-up. Community convention typically suggests 3–6 months between courses, though no washout duration has ever been studied in humans.
Why pulsed:: The original study designs used pulsed courses; the mechanism rationale (if the telomerase hypothesis were true, episodic signaling might suffice) is speculative. The practical reason to pulse is that continuous indefinite use on zero human safety data is harder to justify than a defined course.

Reconstitution at a glance

Mixing math only — the on-page calculator does this live; quick reference for the standard 10 mg vial at the calculator's default mix:

Mixing:: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL (5 mg/mL). On a 100-unit (1 mL) insulin syringe: 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU.
Why this concentration:: At 5,000 mcg/mL the convention doses (0.5–1 mg per injection) fall in the 10–20 IU range on a U-100 syringe — measurable without sub-unit precision. If smaller volumes are preferred, a higher dilution (e.g. 10 mg + 5 mL = 2,000 mcg/mL) spreads the dose across more syringe units, reducing measurement error.

Sources:PMID 12459848 PMID 14523363

Substrate the signal needs

Nutritional cofactor precision

Epitalon is proposed to act on the pineal gland and, separately, on telomerase. Both claims are single-source and unreplicated — but we can still reason from the proposed biology. The useful cofactors either supply the melatonin-synthesis pathway (textbook biochemistry, true regardless of what Epitalon does) or reinforce the proven circadian levers (behaviour, not chemistry). There is no nutritional lever that 'feeds' a telomerase mechanism in people, so the longevity angle gets honest framing rather than a supplement stack.

Reasoned from Epitalon's proposed pineal/circadian and telomerase biology — not an Epitalon cofactor study. The melatonin-synthesis substrate below is textbook biochemistry; the circadian cards are the proven behavioural levers (the one direct test of Epitalon's effect on melatonin secretion found no effect). Supplement doses are common community ranges, not Epitalon-specific findings.

Supply — melatonin-synthesis substrate (L-tryptophan / 5-HTP · vitamin B6 · magnesium)

The pineal gland converts dietary tryptophan → serotonin → melatonin. These three nutrients supply and enable that pathway — true biochemistry independent of whether Epitalon does anything to it.

L-tryptophan or 5-HTP:: Tryptophan is the amino-acid starting material; 5-HTP is one step closer to serotonin and crosses the blood-brain barrier more readily. Community range: L-tryptophan 500–1,000 mg at dinner / 5-HTP 50–100 mg at dinner (choose one; don't combine). Evening timing matches the pineal's natural nighttime activation window.
Vitamin B6 (P5P form):: Pyridoxal-5-phosphate is the active cofactor for the aromatic amino acid decarboxylase enzyme that converts 5-hydroxytryptophan to serotonin. 25–50 mg P5P taken with the tryptophan or 5-HTP dose in the evening.
Magnesium glycinate or threonate:: Magnesium is required for the HIOMT enzyme that converts N-acetylserotonin to melatonin, and independently supports sleep quality and nervous-system tone. 300–400 mg elemental magnesium in the evening — glycinate for sleep, threonate if a cognitive-depth angle is also a goal.

Amplify — the proven circadian levers (behaviour first)

This is the honest cofactor card. The proven way to support the pineal/melatonin system is behavioural. Epitalon's melatonin claim was directly contradicted by the one study that tested it; the light-timing interventions below are not speculative.

Morning bright light (10–30 min within 1 hour of waking):: Direct sunlight or a 10,000 lux light box in the first hour after waking entrains the circadian clock via suprachiasmatic nucleus photoreception — the established upstream signal that sets the nightly melatonin rise. This is the single highest-leverage circadian intervention known, and it is free.
Consistent sleep and wake timing:: The circadian system is a phase-locked oscillator. Irregular sleep timing desynchronizes peripheral clocks from the central SCN signal. Holding the same wake time even on weekends is consistently shown to improve circadian amplitude and melatonin peak.
Evening light reduction (blue-light avoidance from ~9 PM):: Blue-wavelength light (~480 nm) suppresses melatonin onset via the ipRGC/melanopsin pathway. Screen filters, amber-tinted glasses, or dimming overhead lights from two hours before bed measurably advance melatonin onset — the same outcome Epitalon is marketed for, via a proven mechanism.
Why behaviour dominates here:: These three inputs collectively move the melatonin and circadian system substantially and are backed by strong independent evidence. Epitalon's proposed circadian role is, by contrast, built on single-source data and was directly contradicted by a semi-independent melatonin experiment. Treat light and timing as the intervention; Epitalon as optional and speculative alongside them.

Mitigate — minimal for this molecule

Epitalon's reported side-effect profile is thin (the studies are too small and old to characterize it), but the molecule itself is unlikely to deplete specific nutrients.

General longevity substrate:: For anyone using Epitalon in a broader longevity context: adequate protein intake (to support cellular repair), an antioxidant-rich diet (polyphenols, colorful plants), and habitual aerobic exercise address the same 'healthy cellular aging' premise Epitalon is marketed around — with an evidence base that is actually robust. These are not mitigants to Epitalon; they are the proven parallel levers.

Combinations + timing

Stacking notes + timing windows

Epitalon belongs to Vladimir Khavinson's 'short peptide bioregulator' family — the concept is that each 2–4 amino acid peptide is tissue-targeted, and different organs are addressed by different peptides in the family. Community longevity protocols combine them on that rationale. The critical honesty note: pairing single-school bioregulators multiplies speculation, not evidence — every stack member inherits Epitalon's single-source, unreplicated evidence base.

User combinations from the Khavinson bioregulator community — not regimens studied head-to-head. Epitalon itself has zero registered trials and no validated human dose, so any stack is doubly unproven. The cross-links below lead to pages that carry their own honesty framing. Doses are community convention; 'reached for' describes where users go, not a proven indication.

Epitalon + Thymalin (Khavinson thymic bioregulator)

The original pairing in Khavinson's human co-administration work — pineal + thymic bioregulators combined.

Why it works (proposed):: Thymalin is the Khavinson peptide cast as the 'thymic / immune' bioregulator; Epitalon is the 'pineal / circadian' one. The Khavinson human cohort that claimed large mortality reductions used both simultaneously on the 'different tissue, different peptide' rationale — the premise being that systemic longevity requires addressing multiple organ systems at once.
The protocol:: Epitalon 5–10 mg per course (10–20 daily SC injections) paired with Thymalin on a similar injection-course schedule, both repeated periodically (community convention: 1–2 courses per year). Exact doses for Thymalin on its own page.
Outcome:: Reached for in community longevity protocols modeled on the Khavinson administration pattern. Critical caveat: the human study that used this combination studied the pineal extract epithalamin alongside thymalin — not necessarily this synthetic Epitalon — and was unblinded with no design detail reported from the commercializing group. Stacking single-school bioregulators layers speculation onto speculation.

Epitalon + Vilon (Khavinson vascular / immune bioregulator)

Another within-family pairing on the 'different tissue' logic — vascular and immune alongside pineal.

Why it works (proposed):: Vilon (Lys-Glu) is cast as a vascular / immune regulatory peptide in the Khavinson system. Combining it with Epitalon extends the 'cover multiple systems' premise to the cardiovascular / immune angle alongside the pineal angle.
The protocol:: Epitalon and Vilon run as separate injection courses on a periodic schedule — community protocols typically alternate them or run them together seasonally. Doses for Vilon on its own page.
Outcome:: Reached for in extended Khavinson bioregulator longevity stacks. The honest framing applies with full force: every peptide in this family shares the same single-source, unreplicated evidence base, so combining them compounds the speculation rather than cross-validating it.

Epitalon + Pinealon (Khavinson brain / neuroprotective bioregulator)

A within-family pairing targeting both the pineal/circadian system (Epitalon) and the CNS neuroprotective angle (Pinealon).

Why it works (proposed):: Pinealon (Glu-Asp-Arg) is the Khavinson brain-targeted bioregulator, proposed to support neuronal function and neuroprotection. The rationale for combining it with Epitalon is the separate CNS angle — brain tissue alongside the pineal — not overlapping the same proposed lever.
The protocol:: Epitalon injection course (10–20 days SC) plus Pinealon on an equivalent course schedule, repeated periodically. Community conventions vary; doses for Pinealon on its own page.
Outcome:: Reached for in longevity/neuroprotection community protocols. Same caveat as the other within-family pairings: single-school evidence base throughout; no head-to-head combination study exists for any Khavinson peptide pairing.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no modern toxicology program and no long-term human safety dataset for Epitalon. What adverse-event information exists comes from the same small, old, single-group studies that report the efficacy claims, and an independent 2025 review explicitly flags the lack of regulatory-grade toxicology as a gap.

It is important to be clear about what this means: the absence of reported adverse events in tiny, unblinded, decades-old studies is NOT a demonstration of safety. There is no controlled long-term human safety data, no impurity/contamination profile for the research-chemical material now sold online, and no established safe dose. 'Well tolerated' claims for Epitalon are not supported by a real safety database.

The regulatory posture reinforces caution: in 2023 the FDA placed Epitalon on its Category 2 interim list of bulk drug substances (raw active ingredients used to make a medicine) that 'may present significant safety risks.' The FDA removed Epitalon from that Category 2 list in April 2026, with an advisory-committee (PCAC) review scheduled for July 2026 — removal from Category 2 does not by itself authorize compounding. This page presents the available research literature only and makes no therapeutic claim.

Sources:PMID 40141333 FDA human-drug-compounding guidance

As reported in literature

Research dosing ranges

These are the doses actually used in the published studies — the evidence the framing above leans on, shown separately so research data is never mistaken for a human dose. There is no validated human dose for Epitalon and there are no registered clinical trials; the entries below come almost entirely from one research group, in cell culture (in vitro), rodents, or an unblinded human cohort. Note that the human-cohort row studied epithalamin (the pineal extract), not necessarily this synthetic peptide. Milligram 'protocols' and the '~30-minute half-life' figure circulated by vendors are not derived from any primary human pharmacokinetic (drug absorption/clearance) study.

Dose	Route	Model	Outcome	Sources:
Cell-culture exposure	In vitro	Human fetal fibroblasts (cell culture)	Induced hTERT / telomerase activity and telomere elongation; companion paper reported cells overcoming the division limit — single source, not replicated, not in vivo	PMID 12937682
1 mg, 5×/week, lifelong (from ~2 months of age)	Subcutaneous	Mouse — transgenic her-2/neu	Mean/maximum lifespan +13.5%/+13.9%; fewer mammary adenocarcinomas and metastases — Khavinson-lineage, not independently replicated	PMID 12459848
Injectable multi-day courses (IM/SC), repeated over years	Injection (IM/SC)	Human — elderly cohort (n=266); indexed as RCT but no design detail reported	Claimed large mortality reductions over 6–8 years — but for epithalamin (the extract); no blinding/design detail reported, from the commercializing group	PMID 14523363
10⁻⁴–10⁻⁶ M perifusion	In vitro	Rat pineal gland (young + old)	NO significant effect on melatonin secretion at any concentration or age — contradicts the 'restores melatonin' claim	PMID 12809170

Quick answers

Frequently asked

What is Epitalon?

Epitalon (also spelled Epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG). It was developed in Russia by the Khavinson group as a defined analog of epithalamin, a peptide extract of the pineal gland. It is marketed as an anti-aging peptide, most famously as a 'telomerase activator.'

Does Epitalon actually activate telomerase and lengthen telomeres?

The claim comes from a single ~2003 experiment in which Epitalon was added to human fetal fibroblasts in cell culture and induced telomerase (hTERT) activity and telomere elongation. That result is in vitro — cells in a dish, not living people — it came from the group that originated and commercializes the peptide, and it has not been independently replicated. There is no human study showing Epitalon lengthens telomeres in a person.

Why is the 'single-source' issue such a big deal?

Because in science, a claim becomes trustworthy when independent groups reproduce it. Almost all of the positive Epitalon research comes from one research lineage and its affiliated institute — which also sells these peptides — is largely twenty-plus years old, and appears in low-impact translated journals. That is not 'no evidence,' but it is unreplicated, single-source, decades-old evidence, which is far weaker than the confident marketing implies.

Does Epitalon improve sleep or 'reset' melatonin / the body clock?

The evidence actually points the other way on the one direct test. A study (run partly by an outside French chronobiology group) found that Epitalon had NO significant effect on melatonin secretion from pineal tissue, at any dose or age. So the popular 'restores melatonin / resets circadian rhythm' claim is not supported by the experiment that looked at it directly.

Is it true that Epitalon makes people live longer?

There are Khavinson-group reports of reduced mortality in elderly cohorts, but the main human study — though indexed as a randomized trial — reports no blinding or design detail and came from the commercializing group, and it tested epithalamin (the pineal extract), not necessarily this synthetic peptide. There is also rodent data showing roughly a 13% mean-lifespan increase in one mouse strain. None of this is independently replicated, and an unblinded study claiming very large mortality reductions is not credible evidence of a human lifespan effect.

What is Epitalon's half-life, and is it legal?

No validated human pharmacokinetics or half-life has been published — the '~30-minute' figure quoted online is not traceable to a primary human study. Epitalon is not an FDA-approved drug; in 2023 the FDA placed it on its Category 2 interim 503A list, then removed it in April 2026 pending a July 2026 advisory-committee review (removal is not approval). The related epithalamin extract is a registered preparation in Russia, but Epitalon is approved nowhere as a drug outside that context and is sold elsewhere only as a research chemical.

Primary sources

References

PubChem CID 219042PubChem CID 219042 (Epitalon / AEDG; C14H22N4O9, MW 390.35; sequence Ala-Glu-Asp-Gly; CAS 307297-39-8 / 64082-79-7; FDA UNII O65P17785G)
PMID 12937682Khavinson, Bondarev, Butyugov, Bull Exp Biol Med 2003 (Epitalon induces telomerase activity + telomere elongation in cultured human fetal fibroblasts — IN VITRO; single source; not replicated)
PMID 15455129Khavinson, Bondarev, Butyugov, Smirnova, Bull Exp Biol Med 2004 (peptide promotes overcoming the division limit in human somatic cells — same in-vitro fibroblast system)
PMID 14666197Khavinson, Shataeva, Chernova, Bull Exp Biol Med 2003 (hypothesis: regulatory peptides bind promoter sequences to initiate transcription — in silico/in vitro, speculative)
PMID 12809170Djeridane, Khavinson, Anisimov, Touitou, J Endocrinol Invest 2003 (synthetic AEDG had NO significant effect on melatonin secretion in perfused young/old rat pineal — semi-independent; contradicts the melatonin claim)
PMID 14523363Khavinson, Morozov, Neuro Endocrinol Lett 2003 (pineal/thymus peptides 'prolong human life'; n=266 elderly, 6–8 yr; PubMed-indexed as RCT but no blinding/design detail reported; studied epithalamin extract; from the commercializing group)
PMID 12459848Anisimov, Khavinson, Alimova et al., Bull Exp Biol Med 2002 (Epitalon 1 mg SC 5×/wk lifelong; +13.5%/+13.9% mean/max lifespan + fewer tumors in her-2/neu mice — Khavinson lineage; not independently replicated)
PMID 40141333Araj, Brzezik, Mądra-Gackowska, Szeleszczuk, Int J Mol Sci 2025 (independent narrative review: calls Epitalon 'promising' / rationale plausible, while flagging the gaps — decades-old evidence base, limited structural data, no independent replication, no regulatory-grade toxicology)
FDA human-drug-compounding guidanceFDA — Epitalon placed on Category 2 interim 503A bulk drug substances list (2023; 'may present significant safety risks'); removed from Category 2 in April 2026, pending PCAC review 2026-07-24 (removal is not approval)

Research use only · Not medical advice · Updated 2026-06-01